Advanced

Final height after combined growth hormone and GnRH analogue treatment in adopted girls with early puberty

Tuvemo, T; Jonsson, B; Gustafsson, J; Albertsson-Wikland, K; Aronson, AS; Hager, A; Ivarson, S; Kristrom, B; Marcus, C and Nilsson, Karl-Olof LU , et al. (2004) In Acta Pædiatrica 93(11). p.1456-1462
Abstract
Background: Girls adopted from developing countries often have early or precocious puberty, requiring treatment with gonadotrophin-releasing hormone (GnRH) analogues. During such treatment, decreased growth velocity is frequent. Aim: To study whether the addition of growth hormone (GH) to GnRH analogue treatment improves final height in girls with early or precocious puberty. Methods: Forty-six girls with early or precocious puberty (age less than or equal to9.5 y) adopted from developing countries were randomized for treatment for 2-4 y with GnRH analogue, or with a combination of GH and GnRH analogue. Results: During treatment, the mean growth velocity in the GH/GnRH analogue group was significantly higher compared to the control group.... (More)
Background: Girls adopted from developing countries often have early or precocious puberty, requiring treatment with gonadotrophin-releasing hormone (GnRH) analogues. During such treatment, decreased growth velocity is frequent. Aim: To study whether the addition of growth hormone (GH) to GnRH analogue treatment improves final height in girls with early or precocious puberty. Methods: Forty-six girls with early or precocious puberty (age less than or equal to9.5 y) adopted from developing countries were randomized for treatment for 2-4 y with GnRH analogue, or with a combination of GH and GnRH analogue. Results: During treatment, the mean growth velocity in the GH/GnRH analogue group was significantly higher compared to the control group. Combined GH/GnRH analogue treatment resulted in a higher final height: 158.9 cm compared to 155.8 cm in the GnRH analogue-treated group. Three out of 24 girls (13%) in the combined group and nine of the 22 girls (41%) treated with GnRH analogue alone attained a final height below -2 standard deviation scores (SDS). Conclusion: The difference between the two groups is statistically significant, and possibly of clinical importance. A future challenge is to identify a subgroup with clinically significant advantage of GH addition to GnRH analogue treatment. Being very short on arrival in Sweden and being short and young at start of treatment are possible indicators. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
clinical trial, controlled, girls, growth hormone, GnRH analogue, puberty, precocious
in
Acta Pædiatrica
volume
93
issue
11
pages
1456 - 1462
publisher
Wiley-Blackwell Publishing Ltd
external identifiers
  • pmid:15513572
  • wos:000224349500012
  • scopus:7644230926
ISSN
1651-2227
DOI
10.1111/j.1651-2227.2004.tb02629.x
language
English
LU publication?
yes
id
3f9406f6-fa7e-488a-af7c-80f22d03c563 (old id 265496)
date added to LUP
2007-11-03 10:55:26
date last changed
2017-12-10 04:24:29
@article{3f9406f6-fa7e-488a-af7c-80f22d03c563,
  abstract     = {Background: Girls adopted from developing countries often have early or precocious puberty, requiring treatment with gonadotrophin-releasing hormone (GnRH) analogues. During such treatment, decreased growth velocity is frequent. Aim: To study whether the addition of growth hormone (GH) to GnRH analogue treatment improves final height in girls with early or precocious puberty. Methods: Forty-six girls with early or precocious puberty (age less than or equal to9.5 y) adopted from developing countries were randomized for treatment for 2-4 y with GnRH analogue, or with a combination of GH and GnRH analogue. Results: During treatment, the mean growth velocity in the GH/GnRH analogue group was significantly higher compared to the control group. Combined GH/GnRH analogue treatment resulted in a higher final height: 158.9 cm compared to 155.8 cm in the GnRH analogue-treated group. Three out of 24 girls (13%) in the combined group and nine of the 22 girls (41%) treated with GnRH analogue alone attained a final height below -2 standard deviation scores (SDS). Conclusion: The difference between the two groups is statistically significant, and possibly of clinical importance. A future challenge is to identify a subgroup with clinically significant advantage of GH addition to GnRH analogue treatment. Being very short on arrival in Sweden and being short and young at start of treatment are possible indicators.},
  author       = {Tuvemo, T and Jonsson, B and Gustafsson, J and Albertsson-Wikland, K and Aronson, AS and Hager, A and Ivarson, S and Kristrom, B and Marcus, C and Nilsson, Karl-Olof and Westgren, U and Westphal, O and Aman, J and Proos, LA},
  issn         = {1651-2227},
  keyword      = {clinical trial,controlled,girls,growth hormone,GnRH analogue,puberty,precocious},
  language     = {eng},
  number       = {11},
  pages        = {1456--1462},
  publisher    = {Wiley-Blackwell Publishing Ltd},
  series       = {Acta Pædiatrica},
  title        = {Final height after combined growth hormone and GnRH analogue treatment in adopted girls with early puberty},
  url          = {http://dx.doi.org/10.1111/j.1651-2227.2004.tb02629.x},
  volume       = {93},
  year         = {2004},
}